Neuropathic pain

Arizona Legal Cannabis Market Size, Share & Trends Analysis Report 2023-2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 14, 2023
Alternative Medicine, Health, Natural Resources, Cannabis, Recreation, Arizona Department of Health Services, Flower, Medicine, Cheech Marin, Arizona Department, Timeline of cannabis laws in the United States, National University of Natural Medicine, Oil, Goodbody, Arthritis, NCBI, Medication, USD, 2020 Arizona Proposition 207, Government, Pain, Health care, Patient, Neuropathic pain, Pain management, Designer Anabolic Steroid Control Act of 2014, Chronic pain, Cheech & Chong, Drug

The "Arizona Legal Cannabis Market Size, Share & Trends Analysis Report By Source (Marijuana, Hemp), By Product Type (Flowers, Oils And Tinctures), By End-use (Medical, Industrial, Recreational), And Segment Forecasts, 2023-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Arizona Legal Cannabis Market Size, Share & Trends Analysis Report By Source (Marijuana, Hemp), By Product Type (Flowers, Oils And Tinctures), By End-use (Medical, Industrial, Recreational), And Segment Forecasts, 2023-2030" report has been added to ResearchAndMarkets.com's offering.
  • The Arizona legal cannabis market size is projected to reach USD 1,740.2 million by 2030, registering a CAGR of 17.3% from 2023 to 2030.
  • These factors are expected to drive the demand for pain management therapies and contribute to market growth over the forecast period.
  • These products contain prepacked flowers and are available for purchase in New Mexico and Arizona.

Rising Chronic Pain Cases Propel Growth: Pain Patches Market Poised for Steady 4.3% CAGR through 2031 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 6, 2023
Health, Pharmaceutical, Acupuncture, Prevalence, Arthralgia, Marketing, Arthritis, Diabetic neuropathy, Ageing, Market, Government, Compound annual growth rate, Back pain, Traction, Nitroglycerin, Neuropathic pain, OTC, Distribution, Lidocaine, Growth, Chronic pain, Video game, Poultry farming

Pain patches, transdermal solutions designed for controlled pain relief, are gaining traction for their ability to offer continuous medication release.

Key Points: 
  • Pain patches, transdermal solutions designed for controlled pain relief, are gaining traction for their ability to offer continuous medication release.
  • These patches are commonly used for chronic pain conditions like arthritis, back pain, and neuropathic pain, providing a consistent and effective approach to managing discomfort.
  • Market dynamics, including the rise in chronic pain cases and the aging population, contribute to the anticipated growth.
  • Additionally, the elderly are particularly susceptible to chronic pain conditions such as joint pain and neuropathy, propelling market growth.

Tris Pharma Presents Data Reinforcing Limited Abuse Potential of Investigational Pain Therapy Cebranopadol at the 2023 PAINWeek Conference

Retrieved on: 
Tuesday, September 5, 2023
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Ketan, Pharma, Naloxone, Oxycodone, Food and Drug Administration, Opioid use disorder, ADHD, DSM-IV codes, OUD, VAS, FQ, Physical dependence, II, Pain, Visual analogue scale, NOP, Patient, Risk, MOP, Neuropathic pain, Pain management, Addiction, Drug, HAP, FDA, Tramadol, Food, Pharmaceutical industry, Tris

Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain and neurological disorders, today announced new data from a human abuse potential (HAP) study of cebranopadol (TRN-228) which suggest the investigational compound has significantly lower abuse potential compared to both schedule II and schedule IV opioids.

Key Points: 
  • Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain and neurological disorders, today announced new data from a human abuse potential (HAP) study of cebranopadol (TRN-228) which suggest the investigational compound has significantly lower abuse potential compared to both schedule II and schedule IV opioids.
  • The findings will be shared on Thursday, September 7, in a poster presentation at the 2023 PAINWeek conference in Las Vegas.
  • Study participants randomly received a single dose of placebo, cebranopadol 600 μg, cebranopadol 1000 μg, tramadol IR 600 mg or oxycodone IR 40 mg.
  • The difference between the good effects and bad effects of drugs have been linked to their abuse potential.

MIRA Pharmaceuticals and MZ Group Partner to Strengthen Investor Relations and Shareholder Communication Efforts

Retrieved on: 
Tuesday, September 5, 2023
Cognition, Learning, Communication, Partnership, MZ, CB2, CSO, Anxiety, Deficit spending, DSM-IV codes, Appetite, Doctor of Philosophy, Dementia, MD, Patient, Neuropathic pain, CB1, MIRA, Generalized anxiety disorder, THC, Memory, PTSD, Safety, Pharmaceutical industry

BALTIMORE, Sept. 5, 2023 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of a novel synthetic THC analog, today announced its strategic partnership with MZ Group ("MZ"), a renowned international investor relations firm.

Key Points: 
  • BALTIMORE, Sept. 5, 2023 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of a novel synthetic THC analog, today announced its strategic partnership with MZ Group ("MZ"), a renowned international investor relations firm.
  • As part of its commitment to effective communication with its stakeholders, MIRA has joined forces with MZ Group, leveraging their expertise and global presence.
  • MIRA aims to expand its presence in key markets through a comprehensive investor relations and financial communications program.
  • "Our collaboration with MZ Group underscores our commitment to becoming a leader in neurological markets and the expanding cannabis market," said Erez Aminov, Chief Executive Officer of MIRA Pharmaceuticals.

North America Dominates the Global Gabapentin Market with Developed Healthcare System and High Adoption Rates - ResearchAndMarkets.com

Retrieved on: 
Monday, August 7, 2023
Health, Pharmaceutical, Epilepsy, Laboratory, Ciba-Geigy Canada Ltd v Apotex Inc, Gabapentin, Sun Pharma, Policy, Pfizer, USD, Market, Incidence, Hospital, Application, Risk, Neuropathic pain, Aurobindo Pharma, Drug, Growth, Generic, Pharmaceutical industry, Generic drug, Capsule

The global gabapentin market size is expected to reach USD 3.07 billion by 2030, expanding at a CAGR of 5.35% from 2023 to 2030.

Key Points: 
  • The global gabapentin market size is expected to reach USD 3.07 billion by 2030, expanding at a CAGR of 5.35% from 2023 to 2030.
  • The other key growth driver is the rising geriatric population which is more to epilepsy and conditions such as neuropathic pain.
  • Moreover, developed regions such as North America and Europe are further making policy changes to reduce the burden on the healthcare system by promoting the use of generics such as gabapentin.
  • North America is expected to dominate the market over the forecast period, due to a developed healthcare system that facilitates the adoption of drugs such as gabapentin.

NRx Pharmaceuticals Announces the Licensure of a US Patent to Support Use of NRX-101™ for Chronic Pain

Retrieved on: 
Monday, August 7, 2023
SAB, Patent, Rockefeller Neuroscience Institute, Nociception, Spinal cord, Perception, United States Air Force Scientific Advisory Board, NMDA, Research, Brain, CNS, Feinberg School of Medicine, Pain, US, Crave, Thalamus, Neuropathic pain, Ketamine, DCS, License, Northwestern University, Dark Enlightenment, Dietary supplement, Pharmaceutical industry, Vaccine, Anesthesia, Chronic pain, Surgery, Medicine, Northwestern

The patent is supported by extensive nonclinical data and early clinical data that suggest the potential for NMDA antagonist drugs, such as NRX-101 to decrease both chronic pain and neuropathic pain while potentially decreasing craving for opioids.

Key Points: 
  • The patent is supported by extensive nonclinical data and early clinical data that suggest the potential for NMDA antagonist drugs, such as NRX-101 to decrease both chronic pain and neuropathic pain while potentially decreasing craving for opioids.
  • "We delighted welcome Dr. Apkarian to the NRx SAB," said Jonathan Javitt, Chief Scientist and Founder of NRx Pharmaceuticals.
  • "Adding a scientist of Vania's caliber will be invaluable to advancing our clinical program in Chronic Pain."
  • In June 2023, the Company announced a focus on chronic pain as the next focus on NRX-101's development.

Vertex Announces Publication of VX-548 Positive Phase 2, Proof-of-Concept Results in New England Journal of Medicine

Retrieved on: 
Thursday, August 3, 2023
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, The New England Journal of Medicine, Medical Affairs Bureau, Emergency medicine, VRTX, Vertex, Medicine, Associate, NEJM, Harvard Medical School, Pain, Breakthrough therapy, Abdominoplasty, Patient, Manuscript, Hypoventilation, Neuropathic pain, Safety, Vertex Pharmaceuticals, Pharmaceutical industry, Brigham

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced publication in the New England Journal of Medicine (NEJM) of preclinical data and the results from its Phase 2 proof-of-concept trials evaluating treatment with the selective, oral NaV1.8 inhibitor VX-548 for acute pain following abdominoplasty and bunionectomy surgeries.

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced publication in the New England Journal of Medicine (NEJM) of preclinical data and the results from its Phase 2 proof-of-concept trials evaluating treatment with the selective, oral NaV1.8 inhibitor VX-548 for acute pain following abdominoplasty and bunionectomy surgeries.
  • The Phase 2 results from VX-548 show the potential this medicine could bring to patients.”
    Vertex expects to complete the pivotal program in late 2023 and share results from these studies in late 2023 or early 2024.
  • VX-548 has been granted Breakthrough Therapy and Fast Track designations in the U.S. for moderate to severe acute pain.
  • In addition, Vertex has initiated a Phase 2 dose-ranging study of VX-548 in neuropathic pain.

Team from Korea University Medicine Explores Ways to Overcome Cisplatin Resistance and Alleviate Pain in Cancer Treatment

Retrieved on: 
Friday, July 21, 2023
Neoplasm, NANOG, Nature Communications, TRPV1, Epidermal growth factor, Cisplatin, EGF, Transcriptome, Drug resistance, Cervical cancer, Patient, EGFR, Neuropathic pain, Cancer, Attention deficit hyperactivity disorder predominantly inattentive, Metastasis, Platinum, Vaccine

SEOUL, South Korea, July 21, 2023 /PRNewswire/ -- Cisplatin is a widely used chemotherapy drug for various types of cancers. However, frequent usage can lead to the development of drug resistance and neuropathic pain, eventually resulting in treatment failure. In a new study, researchers from South Korea investigated the underlying pathways contributing to this resistance and identified potential therapeutic targets that can be modulated to overcome this. By understanding and targeting these mechanisms, effective treatment strategies can be developed and implemented.

Key Points: 
  • However, frequent usage can lead to the development of drug resistance and neuropathic pain, eventually resulting in treatment failure.
  • But the continued use of cisplatin can lead to the development of cisplatin resistance and other side effects, like chemotherapy-induced neuropathic pain.
  • Now, in a new study, Prof. Tae Woo Kim from Korea University Medicine and his team have explored the pathways leading to cisplatin resistance.
  • This study serves as valuable proof-of-concept for TRPV1 as a therapeutic target to combat cisplatin resistance and neuropathic pain, thereby improving the outlook for patients with cervical cancer.

AxoSim Enters Into a Definitive Agreement to Acquire Vyant Bio's StemoniX Assets

Retrieved on: 
Monday, July 17, 2023
Neuron, Intellectual property, Epilepsy, Neurological disorder, Proiphys, Brain, Doctor of Philosophy, Astrocyte, DSM-IV codes, Cell, Acquisition, Parkinson's disease, Organoid, Neuropathic pain, OTC, Drug discovery, R, ALS, Pharmaceutical industry

NEW ORLEANS and CHERRY HILL, N.J., July 17, 2023 /PRNewswire/ -- AxoSim, Inc., a leader in the development and application of human biomimetic platforms for neurological diseases, and Vyant Bio, Inc. (OTC: VYNT) (Vyant Bio) today announced that they have entered into a definitive agreement under which AxoSim will acquire the microBrain™-associated assets of Vyant Bio's StemoniX subsidiary. The all-cash transaction is expected to close in the next several months, subject to approval by Vyant Bio's shareholders. The companies also announced that effective immediately, AxoSim will have exclusive and sole distribution rights to market the StemoniX microBrain technology platform to pharmaceutical and biotechnology customers. These rights would terminate in the event the transaction is not consummated.

Key Points: 
  • The all-cash transaction is expected to close in the next several months, subject to approval by Vyant Bio's shareholders.
  • The companies also announced that effective immediately, AxoSim will have exclusive and sole distribution rights to market the StemoniX microBrain technology platform to pharmaceutical and biotechnology customers.
  • The StemoniX microBrain technology is a highly scalable iPSC-derived high-throughput neural screening platform coupled with advanced bioanalytical software for phenotypic drug discovery.
  • "We believe that AxoSim is the perfect partner for our StemoniX microBrain technology," said Andrew LaFrence, President, Chief Executive Officer and Chief Financial Officer of Vyant Bio.

Artelo Biosciences Announces Important New Data on ART26.12 Demonstrating Positive Effects in Multiple Models of Neuropathic Pain at the 33rd Annual International Cannabinoid Research Society Symposium

Retrieved on: 
Tuesday, June 27, 2023
Diabetic neuropathy, Chemotherapy-induced peripheral neuropathy, FABP5, The Fear Is Excruciating, but Therein Lies the Answer, Diabetes, Allodynia, Cancer, National Center for Advancing Translational Sciences, Paclitaxel, ICRS, CIPN, Pain, Patient, International Cannabinoid Research Society, Neuropathic pain, FDA, Pharmaceutical industry

SOLANA BEACH, Calif., June 27, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, announced that Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo, presented preclinical data related to ART26.12, Artelo’s novel fatty acid binding protein 5 (FABP5) inhibitor at the 33rd International Cannabinoid Research Society (ICRS) Symposium in Toronto, Ontario, Canada.

Key Points: 
  • There are very limited therapeutic options currently available and these existing treatments are often associated with a significant and undesirable side effect profile.
  • According to Coherent Market Insights , the global neuropathic pain market is estimated to be valued at $7.6 billion.
  • “ART26.12 continues to demonstrate a positive effect in numerous animal models of painful neuropathies, specifically chemotherapy-induced peripheral neuropathy (CIPN) and diabetic neuropathy,” said Professor O’Sullivan.
  • Based on these results, we are highly encouraged by the potential of ART26.12 for the countless patients suffering from this often excruciating and debilitating condition.”